International Project Launched to Sequence Human Microbiome, Share Data



By Catherine Varmazis

Oct. 16, 2008 | In Heidelberg, Germany, today researchers from eight countries and the European Commission announced the formation of a new research enterprise, the International Human Microbiome Consortium (IHMC), which will sequence the genomes of tens of thousands of microorganisms that live in and on the human body and that influence human health.

Initial funding of more than US$200 million is being provided by the U.S. National Human Genome Research Institute (NHGRI) and the European Commission (EC).

Jane Peterson, associate director of extramural research at the NHGRI, said international collaboration is very important in advancing science, and that “the sum is more than the parts.” Participants in the IHMC have agreed in principle to the free and open release of data and resources, and the coordination of research plans, as well as to sharing innovative developments, she reported. Data from microbiome research already being conducted by the NIH Human Microbiome Project and the EC Metagenomics of the Human Intestinal Tract (MetaHIT) project will contribute an initial set of microbial genomes to the IHMC. Because the field is so young – less than three years old – there is much to be gained by collaboration, Peterson said.

Christian Desaintes, from the Research Directorate of the European Commission, said the IHMC’s goal for five years hence is to be sequencing 1000 microbiome genomes from over 1000 individuals’ body parts. The parts in question are the skin, mouth, nasal passages, gastro-intestinal tract, and urogenital tract.

Dusko Ehrlich, coordinator of the MetaHIT project, encapsulated the vast scale of the work to be done: “We know there are 10 times more microbial cells in our bodies than our own cells. We know there are 100 times more microbial genes that are active in our bodies than our own genes. We know that microbes that live within us play an important role in our health and disease. But we do not know by far what these microorganisms are and how they act. The IHMC aims to provide a description of microbial genes and genomes and find how they work.”

The MetaHIT project will contribute to a reference catalog of genes and genomes by analyzing the microbiomes of hundreds of individuals from the Mediterranean region (Spain) and Nordic region (Denmark), initially focusing on two conditions of increasing concern: obesity and inflammatory bowel disease.

Responding to a reporter’s question, the speakers acknowledged that developing countries were conspicuously absent from this project, and that environmental differences are crucial to a full understanding of human disease.  They expressed the hope that interest in the IHMC project would spur additional funding from private sources, to enable less wealthy countries to participate.

One example of the possible relationship between environment and microbiomes was proffered by a researcher from China. He said it is not clear why Chinese who adopt a Western diet tend to develop metabolic diseases of the West that do not affect those who eat only a traditional Chinese diet. He speculated that it might be related to the microbiomes in the gut. By studying the microbiomes of Chinese who eat only a traditional diet, the IHMC project could shed light on this problem.

For more details on today’s announcement, see the press release. 

 

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .